
Opinion|Videos|July 9, 2024
Interchangeability Impacting Biosimilar Uptake
The panel discusses the impact of interchangeability and value of switching studies in biosimilar adoption.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- Has interchangeability impacted biosimilar adoption? If not, why?
- What value do switching studies bring to interchangeable biosimilars?
- Does this data matter more than the designation?
- Do pharmacies and providers value interchangeability?
- Have pharmacies begun acting upon interchangeability with automatic substitutions?
- What value do switching studies bring to interchangeable biosimilars?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves Nerandomilast for Idiopathic Pulmonary Fibrosis
2
Pulling Back Funding for Research Could Leave HIV Treatment in Worse State: Patrick Sullivan, DVM, PhD
3
FDA Approves Cemiplimab as First, Only Adjuvant Immunotherapy for High-Risk CSCC
4
Value-Based Care Interventions and Management of CKD Progression
5